ORIC Pharmaceuticals ORIC Stock
ORIC Pharmaceuticals Price Chart
ORIC Pharmaceuticals ORIC Financial and Trading Overview
| ORIC Pharmaceuticals stock price | 5.1 USD |
| Previous Close | 6.33 USD |
| Open | 6.32 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 800 |
| Day's Range | 6.32 - 6.55 USD |
| 52 Week Range | 2.36 - 6.85 USD |
| Volume | 231.97K USD |
| Avg. Volume | 186.93K USD |
| Market Cap | 289.95M USD |
| Beta (5Y Monthly) | 0.477308 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.83 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.5 USD |
ORIC Valuation Measures
| Enterprise Value | 103M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.076555 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.4295242 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.168 |
Trading Information
ORIC Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.477308 |
| 52-Week Change | 71.46% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.85 USD |
| 52 Week Low | 2.36 USD |
| 50-Day Moving Average | 5.37 USD |
| 200-Day Moving Average | 4.47 USD |
ORIC Share Statistics
| Avg. Volume (3 month) | 186.93K USD |
| Avg. Daily Volume (10-Days) | 375.85K USD |
| Shares Outstanding | 45.09M |
| Float | 26.87M |
| Short Ratio | 40.93 |
| % Held by Insiders | 14.80% |
| % Held by Institutions | 74.00% |
| Shares Short | 4.32M |
| Short % of Float | 10.87% |
| Short % of Shares Outstanding | 9.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.22% |
| Return on Equity (ttm) | -39.44% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -88219000 USD |
| Net Income Avi to Common (ttm) | -89908000 USD |
| Diluted EPS (ttm) | -2.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 189.63M USD |
| Total Cash Per Share (mrq) | 4.21 USD |
| Total Debt (mrq) | 2.68M USD |
| Total Debt/Equity (mrq) | 1.32 USD |
| Current Ratio (mrq) | 12.993 |
| Book Value Per Share (mrq) | 4.498 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -73053000 USD |
| Levered Free Cash Flow (ttm) | -38988876 USD |
Profile of ORIC Pharmaceuticals
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 240 East Grand Avenue |
| ZIP | 94080 |
| Phone | 650 388 5600 |
| Website | https://www.oricpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 88 |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Q&A For ORIC Pharmaceuticals Stock
What is a current ORIC stock price?
ORIC Pharmaceuticals ORIC stock price today per share is 5.1 USD.
How to purchase ORIC Pharmaceuticals stock?
You can buy ORIC shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ORIC Pharmaceuticals?
The stock symbol or ticker of ORIC Pharmaceuticals is ORIC.
Which industry does the ORIC Pharmaceuticals company belong to?
The ORIC Pharmaceuticals industry is Biotechnology.
How many shares does ORIC Pharmaceuticals have in circulation?
The max supply of ORIC Pharmaceuticals shares is 72.34M.
What is ORIC Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
ORIC Pharmaceuticals PE Ratio is now.
What was ORIC Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
ORIC Pharmaceuticals EPS is -1.83 USD over the trailing 12 months.
Which sector does the ORIC Pharmaceuticals company belong to?
The ORIC Pharmaceuticals sector is Healthcare.
ORIC Pharmaceuticals ORIC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Select Market Com NQGS | 8504.39 USD — |
+1.34
|
— — | 8367.19 USD — | 8515.13 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}